Abstracts

526 – Long-Acting Cabotegravir & Rilpivirine: Real-World Outcomes at 3 Years (ANRS CO3 AquiVIH-NA Cohort)

Background Long term safety and virologic outcomes, therapeutic drug monitoring and patient reported outcomes on health-related quality of life and treatment satisfaction of CAB-RPV LA in routine clinical care have rarely been described Methods In the ANRS CO3-AQUIVIH-NA observational cohort in South-Western France, all adults living with HIV who received their first CAB + RPV LA…

798 – Improved Retention After Implementing Differentiated Services for Postpartum Women With HIV in Kenya

Background Differentiated service delivery (DSD) streamlines HIV care for people on antiretroviral therapy (ART) by extending clinic visit intervals and refill durations. HIV treatment guidelines in sub-Saharan Africa, including Kenya, now expand DSD eligibility to include postpartum women with HIV (PPWH). We evaluated DSD implementation and retention in care for PPWH within a large HIV…

256 – Metabolic Dysregulation in HIV: T-Cell Aging Beyond Chronologic Age

Background People with HIV on antiretroviral therapy (PWH) experience premature immune aging driven by chronic immune activation and metabolic dysregulation. T-cell metabolic reprogramming may contribute to immunosenescence. This study evaluated age-related metabolic changes in T cells from PWH compared with HIV-negative controls. Methods We conducted a cross-sectional study including PWH on ART and age- and…

801 – Cost-Effectiveness of Hepatitis C Virus Treatment During Pregnancy

Background Hepatitis C virus (HCV) prevalence among pregnant people in the U.S. increased ten-fold over the past two decades, affecting nearly 0.5% of pregnancies in 2019. While direct-acting antivirals (DAAs) are highly effective, current guidelines diverge. The Infectious Diseases Society of America/American Association for the Study of Liver Diseases endorse shared decision-making, while the American…

1003 – Weight Change After CAB-LA Initiation Among PrEP-Naive Users and Daily TDF/FTC Switchers

Background Weight gain has been reported with integrase inhibitors in HIV treatment, raising concerns for long-acting cabotegravir (CAB-LA) used in HIV prevention. In treatment settings, removal of TDF has also been linked to weight increases, suggesting that switching from daily oral PrEP with TDF/FTC to CAB-LA could alter weight trajectories.  Methods We analyzed a prospective…

265 – Enhanced IL-32 Expression Across Immune Cells Shapes Cytokine Responses and HIV Control Persistence

Background Spontaneous HIV controllers suppress viremia without antiretroviral therapy, yet many eventually lose control. The mechanisms that sustain long‐term suppression remain unclear. IL-32, an intracellular cytokine that influences both antiviral defences and immune regulation, has been implicated in HIV pathogenesis and the transition from control to progression. We hypothesize that host genetic and non-genetic factors…

547 – The Dose-Response Curve Slope Quantifies Lenacapavir’s In Vivo Inhibition of HIV-1

Background Lenacapavir (LEN), a first-in-class HIV-1 capsid inhibitor, is unique in that it can inhibit HIV-1 infection through multiple mechanisms, affecting both early and late stages of the viral life cycle. The efficacy of LEN can be best understood using a previously described metric, Instantaneous Inhibitory Potential (IIP), which includes the dose response curve slope,…

842 – Harnessing Proviruses to Define bNAb Sensitivity in Infants With In-Utero HIV-1 (IMPAACT P1115)

Background Broadly neutralizing antibodies (bNAbs) are under study to enable ART-free remission in perinatal HIV-1. Phenotypic testing would guide targeted bNAb therapy but is limited by low assay yields and plasma volume in children. These barriers may be overcome with a proviral sequencing approach. Methods bNAb sensitivity was assessed using near full-length single genome sequencing on…

608 – Extracellular Vesicle-Associated PD-L1 as a Biomarker of Hepatocarcinogenesis in HIV/HCV Coinfection

Background Despite achieving sustained virologic response (SVR) with direct-acting antivirals (DAA), individuals HCV/HIV+ with cirrhosis remain at risk of developing hepatocellular carcinoma (HCC). Identifying biomarkers that anticipate HCC onset is therefore crucial. We have previously reported that plasma extracellular vesicles (pEV) from individuals HCV/HIV+ who later developed HCC downmodulate NK cell function. The aim of…

1087 – Expected Impact of Twice-Yearly Lenacapavir on PrEP Coverage Disparities and HIV Incidence in the US

Background The Ending the HIV Epidemic plan (EHE) aims to reduce HIV incidence by 90% from 2017 to 2030 via improved testing, treatment, and use of pre-exposure prophylaxis (PrEP). Challenges with PrEP uptake and adherence among populations with the greatest need have limited EHE progress to date. New PrEP products, such as twice-yearly injectable lenacapavir…